Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

BACKGROUND: TRIBE and TRIBE-2 studies demonstrated higher benefit from FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/bevacizumab compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX/bevacizumab as an upfront option for metastatic colorectal cancer patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., Marmorino, F., Zaniboni, A., Buonadonna, A., Masi, G., Lonardi, S., Pietrantonio, F., Falcone, A., Antonuzzo, A., Cremolini, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551530/
https://www.ncbi.nlm.nih.gov/pubmed/34689001
http://dx.doi.org/10.1016/j.esmoop.2021.100293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551530/
https://www.ncbi.nlm.nih.gov/pubmed/34689001
http://dx.doi.org/10.1016/j.esmoop.2021.100293

Ejemplares similares